The QualityStocks Daily Monday, September 21st, 2020

Today's Top 3 Investment Newsletters

HotMicrocap Stocks (GWHP) +42.03%

MarketClub Analysis (CUB) +34.23%

QualityStocks (RPMT) +31.50%

The QualityStocks Daily Stock List

Acquired Sales Corp. (AQSP)

MarketWatch, Real Investment Advice, Research Pool, Wallet Investor, Market Exclusive, Street Insider, Marijuana Stock Review, Central Charts, Nasdaq, Barchart, Wall Street Analyzer, 4-Traders, Simply Wall St, GlobeNewswire, Stockopedia, Market Screener, FX Empire, Investors Hangout, last10k, InvestorsHub, Stockhouse, MarketBeat, Seeking Alpha, OTC Dynamics, GuruFocus, Dividend.com, Wallmine, Morningstar, Dividend Investor, Green Market Report, YCharts, and Business Wire reported beforehand on Acquired Sales Corp. (AQSP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Acquired Sales Corp. is a consolidator of companies making branded cannabinoid-infused products. These products include beverages, muscle/joint rubs, oils, crystals, tinctures, bath bombs, and isolate. Additionally, products include relief balms, elixirs, body washes, med sticks, lotions, vape pens and cartridges, shatter, and gummies. On February 24, 2020, the Company acquired 100 percent of fast growing and profitable Warrender Enterprise, Inc. d/b/a Lifted Made (formerly d/b/a Liquids), of Zion, Illinois. Acquired Sales has its corporate headquarters in Lake Forest, Illinois.

The Company believes in the value of cannabinoids (CBD, CBG, CBN, etc.). Furthermore, it owns 4.99 percent of CBD-infused beverage and products maker Ablis Holding Company, and of craft distillers Bendistillery, Inc. d/b/a Crater Lake Spirits and Bend Spirits, Inc., Bend, Oregon, that it purchased on April 30, 2019 for $1,896,200 in cash.

The Company’s House Brands include Lifted Made. This is the distinguished house of creative cannabis products targeting astute consumers who demand the highest quality products, speedy delivery systems, and lasting effects.

Moreover, House Brands include Levé-Pâte De Fruit. Levé is a cannabis-infused confectionary brand, centered around the highest quality vegan ingredients imported from France. Another House Brand is Urb-Finest Flower. Urb is an exclusive cannabis hemp flower brand. Urb is focused around supporting U.S. farmers, using rare hemp genetics (strains) paired with one-of-a-kind packaging.

In July, Lifted Made announced its launch of the world’s first hemp-derived delta-8-THC nano-particle drops under Lifted Made’s flagship brand Urb Finest Flowers. Urb’s delta-8-THC nano drops are a flavored, water soluble tincture and beverage additive, and are federally legal. The nano drops sell in a one ounce bottle and contain 333 mg. of delta-8-THC and less than 0.3% delta-9-THC. At present, the product is available for purchase in three flavors: Go Grape, Let’s Mango, and Orange Dream.

Moreover, in July, Lifted Made announced its launch of flavored nano CBD water enhancer packets under Lifted Made’s flagship brand Urb Finest Flowers. Urb’s nano CBD water enhancer packets are water soluble and are available in four flavors. These are mango, blue razz, watermelon, and lemon. Each packet contains roughly 10 mg. of CBD, and less than 0.3% delta-9-THC.

Acquired Sales Corp. (AQSP), closed Monday's trading session at $1.51, even for the day, on 50 volume. The average volume for the last 3 months is 379 and the stock's 52-week low/high is $1.25/$5.00.

Community Bankers Trust Corporation (ESXB)

Wealth Daily, The Fly, Market Chameleon, Street Insider, InvestorsHub, Equity Clock, YCharts, MarketPanorama, Stockwatch, Dividend Channel, Business Wire, ETF.com, Annual Reports, Morningstar, EarningsCast, Investors Observer, Stocklight, Investing.com, TradingView, Seeking Alpha, Finviz, GuruFocus, PR Newswire, Stockhouse, Nasdaq, TMXmoney, Dividend.com, last10k, Insider Tracking, Market Screener, Dividend Investor, GuruFocus, and Simply Wall St reported previously on Community Bankers Trust Corporation (ESXB), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Community Bankers Trust Corporation is the holding company for Essex Bank. Essex Bank is a Virginia State bank with 24 full-service offices, 18 of which are in the State of Virginia, and six of which are in the State of Maryland. Furthermore, the Bank operates two loan production offices. Founded in 1926, Community Bankers Trust Corporation is based in Richmond, Virginia. It is a well-capitalized single bank holding Company. The Company lists on the NasdaqCM.

Essex Bank provides financial services primarily to individuals, small businesses, and also commercial enterprises. The Bank provides individual and commercial demand and time deposit accounts; and commercial and industrial loans, consumer and small business loans, and real estate and mortgage loans. In addition, the Bank provides investment services; online and mobile banking products; cash management services; as well as insurance and investment products.

Recently, Community Bankers Trust Corporation announced that its Board of Directors declared a quarterly dividend of $0.05 per share regarding the Company's outstanding common stock. The dividend was payable on September 1, 2020, to shareholders of record at the close of business on August 21, 2020.

On July 30, 2020, Community Bankers Trust Corporation reported results for Q2 and the first six months of 2020.

Mr. Rex L. Smith, III, President and Chief Executive Officer of Community Bankers Trust Corporation, stated, "The second quarter showed numerous positive changes from the first quarter, although the ongoing effects of the pandemic are yet to be known. Even in this challenging environment, we were able to create core earnings and growth in overall value. Net income increased by $2.7 million from the first quarter to $4.2 million for the second quarter. We continue to focus on supporting our clients and our communities. We originated over $83 million in PPP loans, and we worked with our customers in highly affected industries to keep their businesses operating by granting some form of payment relief to 249 loans totaling $170 million."

Community Bankers Trust Corporation (ESXB), closed Monday's trading session at $5.13, off by 0.965251%, on 73,579 volume with 679 trades. The average volume for the last 3 months is 70,209 and the stock's 52-week low/high is $4.00/$9.75.

Hall of Fame Resort & Entertainment Company (HOFV)

Stocktwits, Financial Buzz, Finviz, Stock Analysis, Invest Million, PR Newswire, Market Screener, Seeking Alpha, Business Wire, TMCnet News, Stocklight, InvestorsHub, Simply Wall St, Nasdaq, Fintel, Stockopedia, OTC Markets, Investors Observer, Biz Journals, and MarketWatch reported earlier on Hall of Fame Resort & Entertainment Company (HOFV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Hall of Fame Resort & Entertainment Company is the only resort, entertainment, and media company centered around the power of professional football. It is owner of the Hall of Fame Village powered by Johnson Controls in Canton, Ohio. It leverages the strength and popularity of professional football and its legendary players in partnership with the Pro Football Hall of Fame. Hall of Fame Resort & Entertainment is based in Canton, Ohio. The Company’s shares trade on the NadaqGS. Established in 2015, the Company went public in a reverse merger transaction in 2020.

The publicly traded Company is the result of a merger between HOF Village, LLC., a partnership between the Pro Football Hall of Fame and Industrial Realty Group (IRG) that started in 2016 and Gordon Pointe (GPAQ) Acquisition Corp. Its corporate vision is to create a one-of-a-kind resort and entertainment enterprise.

The Company has added to its on-campus assets, Tom Benson Hall of Fame Stadium and the National Youth Football and Sports Complex, with the acquisition and renovation of the Hilton DoubleTree hotel in downtown Canton, Ohio. It is working with numerous financial partners to finalize funding for the development of The Constellation Center for Excellence, the Hall of Fame Premium Hotel, the Hall of Fame Waterpark, the Hall of Fame Retail Promenade, and the Center for Performance.

Hall of Fame Resort & Entertainment Company acquired a majority interest in The Crown League, a professional football fantasy league, and 100 percent of Youth Sports Management LLC. The NFL Alumni Association headquarters and the NFL Alumni Academy complex are moving to the Hall of Fame Village powered by Johnson Controls, along with additional youth and player programming.

This month, Hall of Fame Resort & Entertainment Company announced that it named experienced business professional Ms. Erica Muhleman as its Executive Vice President of New Business Development/Marketing & Sales, effective September 14, 2020. Ms. Muhleman’s chief responsibilities will include expanding and strengthening the Company’s relationships with international, national, and regional business partners to boost revenue and raise Hall of Fame Resort & Entertainment Company’s brand profile. Ms. Muhleman brings to the Company wide-ranging knowledge of corporate sponsorships, sales and marketing, and community and public relations accumulated from her more than 20 years of experience working in the sports and entertainment industries.

Hall of Fame Resort & Entertainment Company (HOFV), closed Monday's trading session at $3.14, off by 12.5348%, on 347,580 volume with 2,036 trades. The average volume for the last 3 months is 407,944 and the stock's 52-week low/high is $3.1400001/$12.3100004.

Jaguar Health, Inc. (JAGX)

Alpha Stock News, BioSpace, Stocktwits, Market Chameleon, BioPharmaJournal, Infront Analytics, Stock Consultant, Central Charts, Investors Observer, Investing.com, InvestorsHub, Stockhouse, iwatchmarkets, Proactive Investors, Webull, Wallet Investor, TradingView, GuruFocus, Stockwatch, Street Insider, and Stockopedia reported beforehand on Jaguar Health, Inc. (JAGX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Jaguar Health, Inc. is a commercial stage pharmaceutical company centered on developing novel, sustainably derived gastrointestinal products on an international basis. Its wholly-owned subsidiary is Napo Pharmaceuticals, Inc. Napo focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Founded in 2013, Jaguar Health is based in San Francisco, California. The Company lists on the NasdaqGS.

Jaguar Health’s corporate mission is to identify human and animal health market opportunities where it can develop targeted products, which take advantage of its broad intellectual property (IP) portfolio, deep pipeline, and extensive botanical library. The Company’s focus is naturally derived health solutions for humans and animals.

The Company’s Mytesi® (crofelemer) product is approved by the U.S. FDA (Food and Drug Administration) for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. MYTESI® is not indicated for the treatment of infectious diarrhea. Crofelemer comes from the Croton lechleri tree, which is responsibly and sustainably harvested in South America.

In August, Jaguar Health announced that it submitted to the FDA's Center for Veterinary Medicine (CVM) the last required technical section to support approval of the Company's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs. According to present estimates, greater than 230,000 dogs in the United States receive chemotherapy treatment for different cancers each year. About one in four (over 50,000 dogs) will experience diarrhea as a side effect of treatment. Further to pursuing an indication for CID in dogs, Jaguar Health is also seeking conditional approval to market Canalevia for exercise-induced diarrhea (EID) in dogs.

Earlier in September, Jaguar Health announced the launch of its mental health Entheogen Therapeutics Initiative (ETI), which aims to discover and develop pioneering, novel, natural medicines derived from psychoactive plants for the treatment of mood disorders, neuro-degenerative diseases, addiction, and also other mental health disorders. The initiative will first concentrate on plants from Jaguar's proprietary library of 2,300 plants, with the aim of identifying plants that may have the potential to treat mood disorders.

Jaguar Health, Inc. (JAGX), closed Monday's trading session at $0.36, up 0.558659%, on 1,016,923 volume with 1,319 trades. The average volume for the last 3 months is 5,908,268 and the stock's 52-week low/high is $0.300000011/$1.58000004.

Minera Alamos, Inc. (MAIFF)

Northern Miner, Gold Stock Data, InvestorX, StreetWise Reports, Proactive Investors, Wallet Investor, Mexico Mining Center, YCharts, Newsfilecorp, GuruFocus, GlobeNewswire, Investing.com, Stockwatch, 4-Traders, Stockhouse, PR Newswire, Money.Tmx.com, 24hgold, Business Insider, Proven and Probable, Canadian Insider, and Geology for Investors reported previously on Minera Alamos, Inc. (MAIFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Minera Alamos, Inc. engages in the acquisition, exploration, as well as development of mineral properties in Mexico. The Company has an increasing portfolio of high-quality Mexican assets. This includes the La Fortuna open pit gold project in Durango and the Santana open pit heap-leach development project in Sonora. An advanced-stage exploration and development company, Minera Alamos is based in Toronto, Ontario. The OTCQB-listed Company was formerly known as Virgin Metals, Inc. It changed its corporate name to Minera Alamos, Inc. in May of 2014.

Minera Alamos’ strategy is to develop low capex (capital expenditure), high margin assets with expansion opportunities. This is while continuing to pursue complementary strategic acquisitions.

The La Fortuna open pit gold project in Durango has a positive PEA (Preliminary Economic Assessment) completed (permits granted). The La Fortuna project is 6,200 ha. Minera Alamos acquired 100 percent of the 4 mining concessions, which comprise the La Fortuna project in May of 2016 from Argonaut Gold, Inc. The concessions are subject to a 2.5 percent NSR (Net Smelter Return) on production to a maximum of US$4.5M payable to Argonaut Gold. A construction decision on La Fortuna could be made in late 2020 or early 2021.

The Santana open pit heap-leach development project in Sonora has test mining and processing completed (permits pending). The Santana project is 8,500 ha. It is strategically positioned in a rich mining district. The district features operational mines from some of the world’s foremost names in precious metals mining (Goldcorp, Agnico Eagle, Alamos Gold). Santana is presently under construction, and is expected to have its first gold production in early 2021.

Last week, Minera Alamos announced it is continuing to review and compile the remaining historical drill data from the Cerro de Oro gold project in Zacatecas, Mexico. This project is less than 3km from the town of Melchor Ocampo and about 30 km from the district's mining hub at Concepcion del Oro. This area of north-central Mexico is well-known for its mineral production, most notably related to gold and silver rich-intrusive-related deposits.

Of specific note are several close by large-scale mining operations. These include Peñasquito (Newmont) just 30km away; Tayahua (Frisco); Noche Buena (Fresnillo); and also Camino Rojo (Orla). The newly acquired 100 percent-owned Cerro de Oro oxide gold project in northern Zacatecas has substantial past drilling and metallurgical work completed. It could enter the permitting process quickly.

Minera Alamos, Inc. (MAIFF), closed Monday's trading session at $0.4879, off by 7.9434%, on 678,967 volume with 231 trades. The average volume for the last 3 months is 313,890 and the stock's 52-week low/high is $0.11157/$0.596000015.

NuVista Energy Ltd. (NUVSF)

Tech Know Bits, EnergyNow.ca, TeleTrader, Capital Cube, Street Insider, TipRanks, Invezz.com, Invest Tribune, Stockchase, Macroaxis, MarketWatch, FX Empire, Investors Hangout, Morningstar, Wallet Investor, Financial Post, Dividend Investor, Dividata, GlobeNewswire, The Fly, Stockhouse, Market Screener, Nasdaq, and TMXmoney reported beforehand on NuVista Energy Ltd. (NUVSF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

NuVista Energy Ltd. is an oil and natural gas company based in Calgary, Alberta. It engages in the exploration for, and the development and production of, oil and natural gas reserves in the Western Canadian Sedimentary Basin. Its primary focus is on the scalable and repeatable condensate-rich Montney formation in the Alberta Deep Basin (Wapiti Montney). Established in 2003, NuVista Energy lists on the OTC Markets.

The Company’s aim is to operate with a high working interest (WI) ownership. This enables it to control the pace of development, minimize costs and cycle times between ideas and cash flow, and permits NuVista Energy to accurately forecast the timing and magnitude of its efforts.

NuVista is advancing its Wapiti Montney condensate-rich natural gas resource play. This play has strong economics and significant upside potential. Condensate is important to the heavy oil business as heavy oil bitumen must be combined with condensate to create the viscosity needed to allow transportation on pipelines. Condensate sales account for more than 60 percent of NuVista Energy Revenues.

Concerning Wapiti Montney, NuVista Energy holds rights in approximately 166,720 gross acres of land, which are prospective for the Triassic Montney formation with an approximate working interest (WI) of 89.8 percent. The Montney formation in this region is typified by high rate condensate-rich natural gas.

Additionally, the Company has roughly 1,600 Boe/d of net production from different other Triassic zones on 52,800 net acres of non-Montney land. These Assets are to the northeast of the Pipestone Montney acreage. They consist of mainly non-operated, low decline unit production with below industry average asset retirement obligations.

Furthermore, included is a 39 percent operated WI in the area gathering and compression system and the Wembley gas plant. Also, NuVista has non-core operations in three additional areas of Alberta whose combined production in 2017 averaged 900 Boe/d versus 2,761 Boe/d in 2016 due to asset divestitures and production decline.

Last month, NuVista Energy announce results for the three and six months ended June 30, 2020 and provide an update on its future business plans. The Company took decisive action in the face of a challenging quarter for all of the industry, via the implementation of a COVID-19 safe operating plan, the restriction of higher condensate ratio production during the lowest oil/condensate commodity value periods, and the considerable reduction of capital, operating, and G&A spending to ensure liquidity and balance sheet protection remained vital.

During the quarter ended June 30, 2020, NuVista Energy produced at a restricted average rate of 50,922 Boe/d, alike to the comparative period in 2019 and Q1 of 2020. The Company achieved adjusted funds flow of $15.1 million ($0.07/share, basic); and realized operating expenses of $9.66/Boe because of cost reduction efforts, and one-time prior period adjustments, partially offset by the effect of decreased production volumes. Moreover, it realized a net G&A expense of $0.87/Boe, a reduction of 22 percent from the previous period.

NuVista Energy Ltd. (NUVSF), closed Monday's trading session at $0.5224, off by 7.0198%, on 18,601 volume with 15 trades. The average volume for the last 3 months is 16,430 and the stock's 52-week low/high is $0.170000001/$2.48015999.

Town Sports International Holdings, Inc. (CLUB)

Stocktwits, MarketWatch, Invest Chronicle, Market Screener, ChartMill, Nasdaq, Finviz, Simply Wall St, YCharts, MarketBeat, DBT News, Seeking Alpha, Fintel, Morningstar, GuruFocus, Finbox, Business Wire, Stockhouse, PitchBook, and Annual Reports reported earlier on Town Sports International Holdings, Inc. (CLUB), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Town Sports International Holdings, Inc. is a diversified holding company listed on the NasdaqGM. Its subsidiaries engage in several business and investment activities. The Company’s corporate structure provides flexibility to make investments across a wide array of industries in order to create long-term value for shareholders.

Town Sports International is led by its Chief Executive Officer and Chairman of the Board, Mr. Patrick Walsh. Town Sports International Holdings has its corporate headquarters in Jupiter, Florida.

Town Sports’ largest operating subsidiary, TSI, LLC, has been involved in the fitness industry since 1973. Moreover, it has grown to become one of the largest owners and operators of fitness clubs in the Northeast region of the United States.

The Company's clubs offer special purpose rooms for group fitness classes; and other exercise programs, and also accommodate cardiovascular and strength-training equipment. Furthermore, its clubs provide amenities, including swimming pools, racquet and basketball courts, and functional training zones.

They also provide babysitting services; and fee-based program services that consist of personal and small group training, children's programs, and summer camps for kids. The Company sells its memberships by way of direct sales at the club level, and also corporate and group sales; and via its Websites.

This month, Town Sports International Holdings reported results for Q1 of 2020. In response to the COVID-19 pandemic, the Company proactively closed all of its clubs system wide by March 22, 2020, the majority of which remain closed through the date of this filing.

Town Sports International has not recognized Q1 Revenue related to monthly membership dues collected in March before clubs closed. It plans to re-open clubs once local authorities issue guidelines authorizing the reopening of fitness centers and the Company ascertains it is safe to do so. The March deferrals have had a considerable impact on its Q1 financial results.

The Company states that the duration of the COVID-19 pandemic and the extent of its effect on its business cannot be reasonably estimated at this time. Town Sports anticipates that the COVID-19 pandemic will continue to negatively impact its operating results in future periods.

Town Sports International Holdings, Inc. (CLUB), closed Monday's trading session at $0.2969, off by 5.0831%, on 1,066,708 volume with 1,599 trades. The average volume for the last 3 months is 2,373,712 and the stock's 52-week low/high is $0.194999992/$3.00.

Oliveda International, Inc. (OLVI)

Spotlight Growth, OTC Dynamics, TeleTrader, GuruFocus, TipRanks, Stockopedia, EIN Presswire, TradingView, The Richard Rose Report, Equity Clock, InvestorsHub, OTC.Watch, Stockhouse, Seeking Alpha, Wallet Investor, Barchart, Morningstar, Nasdaq, and Stockwatch reported previously on Oliveda International, Inc. (OLVI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Oliveda International, Inc. is a leading international natural cosmetics innovator in the premium segment. It has also developed a globally innovative wearable beauty and health technology. Through subsidiary operations, the Company is the largest investor in eco-certified mountain olive trees and the largest conservationist in Arroyomolinos de Leó, Spain. German real estate investor Mr. Thomas Lommel founded Oliveda International in 2003. Oliveda International is based in Santa Monica, California.

The Company generates online sales and has a worldwide branch network of 650 retail stores. Its wholly-owned Oliveda Deutschland GmbH subsidiary operates flagship stores, Olive Tree Pharmacy, in Berlin and Dusseldorf. It has plans to open new locations in Los Angeles, Taipei and Seoul.

Overall, Oliveda International believes that it will be able to operate a total of 60 of its own flagship stores around the world. In addition, it believes that it will be able to increase the retail store network globally to 1,200 over the next five years.

On September 1, 2015, Oliveda International opened its first flagship Store in the Neue Schönhauser Str. 11 in Berlin-Mitte. With this opening, the concept of the Company’s Olive Tree Pharmacy came to fruition. In Olive Tree Pharmacy Stores, visitors are counseled in the holistic advantages of Oliveda International’s Olive Tree Therapy, and given a sense of its encompassing effects. Furthermore, the Company supplies visitors with Olive Tree Home Therapy Sets, custom-made to suit their personal needs.

Oliveda International launched many new products in 2019. This included its Beauty Molecule that was met with immediate success, entering Oliveda’s Top 10 bestselling products within just a few weeks. Furthermore, new companies and brands have been developed in 2020, including LA DOPE, Olive Tree People, and Oliveda America. New innovative technologies were also developed, as well as sales contracts for more than 20,000 of the Company’s own mountain olive trees.

Last week, Oliveda International reported additional sales growth in Q1 of 2020, with Income increasing 15 percent and Net Income increasing close to 75 percent over the same period in 2019. This continued growth comes at a time when many retailers are struggling because of the COVID-19 pandemic. Even with most stores closed, Oliveda International is experiencing strong online sales in Q2. The Company expects even better results once that period is reported in August 2020.

Oliveda International, Inc. (OLVI), closed Monday's trading session at $0.07, up 39.7206%, on 13,800 volume with 5 trades. The average volume for the last 3 months is 4,940 and the stock's 52-week low/high is $0.012799999/$0.148000001.

Lake Resources N.L. (LLKKF)

Penny Stock Hub, Stockhouse, Investing News, OTC Markets, Nasdaq, TipRanks, TeleTrader, Investors Hangout, Wallet Investor, Morningstar, Stockwatch, Proactive Investors, Simply Wall St, GuruFocus, InvestorsHub, OTC.Watch, Barchart, Market Screener, TradingView, Dividend Investor, Baystreet.ca, and Seeking Alpha reported earlier on Lake Resources N.L. (LLKKF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lake Resources N.L. is an Australian mining company centered on the development of lithium projects. Four of its five projects are in Argentina within South America’s Lithium Triangle, which holds more than 50 percent of the globe’s lithium resources. Lake Resources has the largest lithium lease holding in Argentina. Its acreage totals close to 2,000 sq., km and is 100 percent owned and operated by Lake Resources. OTCQB-listed, the Company is based in Sydney, New South Wales.

Lake Resources’ portfolio provides exposure to brines and pegamatites. This portfolio is in close proximity to some of the world’s leading lithium companies. These include SQM, Lithium Americas, Orocobre, and Advantage Lithium.

Lake Resources’ Lithium Brine Projects include the Cauchari Project (10 sq. km), Jujuy Province; the Olaroz Project (180 sq. km), Jujuy Province; the Paso Project (290 sq. km), Jujuy Province; and the Kachi Project (690 sq. km), Catamarca Province. The Company’s Lithium Pegmatite Project is the Catamarca Project (720 sq. km), Catamarca Province.

In November of 2018, Lake Resources announced a maiden JORC resource at its Kachi Project of 4.4 million tonnes (Mt) of contained lithium carbonate equivalent (LCE), and an exploration target ranging between 8-17Mt of LCE. This ranks Kachi as one of the world’s top 10 brine resources. The project is about 100km south of FMC’s Hombre Muerto lithium brine operation.

Lake Resources announced in January of this year a major step forward. It confirmed that battery grade lithium carbonate with 99.9 percent purity was produced with very low impurities from its Kachi Lithium Brine Project using Lilac Solutions’ disruptive technology in California. Lithium carbonate with 99.9 percent purity surpasses the industry standard specifications for battery-grade purity (>99.5 wt percent).

Recently, Lake Resources announced it will be presenting at the Planet MicroCap Showcase 2020 on Wednesday, April 22 at 6.00PM EST. Mr. Stephen Promnitz (Chief Executive Officer/MD of Lake Resources NL) will be hosting the presentation and answering questions from investors. One on one meetings will be scheduled and conducted by way of private, secure video conference through the conference event platform.

Lake Resources N.L. (LLKKF), closed Monday's trading session at $0.0689, up 35.098%, on 1,756,726 volume with 146 trades. The average volume for the last 3 months is 160,113 and the stock's 52-week low/high is $0.015499999/$0.324400007.

Full Alliance Group, Inc. (FAGI)

Penny Stock Base, Stock Scores, TipRanks, Market Screener, StockAP, Insider Financial, StockInvest.us, Morningstar, Stockhouse, Stockwatch, GuruFocus, Clay Trader, 4-Traders, Investors Hangout, Dividend Investor, GlobeNewswire, and InvestorsHub reported earlier on Full Alliance Group, Inc. (FAGI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Full Alliance Group, Inc. is a multi-faceted holding company listed on the OTC Markets. It has various interests in technology, healthcare, and nutraceuticals. Nutra Yu, Inc. is a wholly owned subsidiary of Full Alliance Group. EBO2, Inc., is also a wholly owned subsidiary of the Company. Full Alliance Group has its corporate headquarters in Palm Desert, California.

The Company’s Nutra Yu subsidiary develops, markets, and distributes a proprietary line of nutraceutical products. The EBO2 subsidiary is the provider of ''EBO2'', a modern high volume blood gas exchange unit for the treatment of 5-7 liters of blood with medical ozone. The unit allows extracorporeal blood and oxygenation and ozone exposure and blood filtration through the filter in an innovative way by using the integrated diffusing membranes within the filter fibers to trap lipids and proteins that are in excess in the venous blood supply.

The EBO2 unit is considered the world's most advanced medical ozone therapy performed today. The EBO2 procedure is a minimally invasive intravenous therapy alike to hemodialysis developed as a treatment for numerous cardiological problems, allowing the patient to avoid life threatening, highly risky, painful, costly and complicated surgeries and long recovery periods.

Full Alliance Group’s mission is to provide technologically advanced, natural, nutritional products of unrivaled formulation, and also to educate consumers and healthcare practitioners in preventative healthcare and in bio-energetic systems for integrating overall wellness. The Company’s industries include Health & Wellness, Orthomolecular Medicine, Cardiovascular Health, Traditional Chinese Medicine (TCM), Nutraceuticals, and Quantum Energetic Medicine.

This past May, Full Alliance Group announced that Nutra Yu launched new sales and marketing initiatives for its Dr. Louie Yu Formulations™ brand of proprietary nutraceutical products on several online retail platforms. Nutra Yu, Inc. was founded by Dr. Yu to further develop, market, and distribute his proprietary line of nutraceuticals. Nutra Yu's "Dr. Louie Yu Formulations" are a complete product line of inventive all-natural nutraceuticals founded on the science of Traditional Chinese Medicine (TCM), Western orthomolecular concepts, as well as modern-day physics.

Recently, Full Alliance Group announced it appointed Matthew Cook, MD, and Dr. Leonid Macheret to its Medical Advisory Board. Dr. Cook is the Founder of BioReset Medical Corporation and as acting President, operates a Regenerative Medicine and Pain Medicine practice, which provides pioneering non-surgical solutions in orthopedic medicine, sports medicine, regenerative pain medicine, and stem cell medicine.

Dr. Macheret is the Medical Director of Partners In Wellness, Inc. This is an innovative healthcare environment combining holistic healing with today's conventional medical practices. Partners In Wellness specializes in treating chronic illness and pain, fibromyalgia, chronic fatigue syndrome (CFS), nutrition, and non-surgical joint regeneration.

Full Alliance Group, Inc. (FAGI), closed Monday's trading session at $0.012, up 41.1765%, on 293,353 volume with 11 trades. The average volume for the last 3 months is 311,463 and the stock's 52-week low/high is $0.004999999/$0.254999995.

CLIC Technology, Inc. (CLCI)

Investing News, Stockhouse, Street Insider, Stockwatch, Stock of the Week, Make Penny Stocks Great Again, OTC Market Research, GuruFocus, PennyStocks.News, BlockChainWire, InvestorsHub, and Simply Wall St reported previously on CLIC Technology, Inc. (CLCI), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A "Financial Technology" company, CLIC Technology, Inc. is the developer and marketer of new, pioneering blockchain products and services. It has created an innovative "crypto-payment gateway system." This system enables consumers to use cryptocurrency to make routine purchases online. The system enables merchants to accept crypto payments and receive immediate settlements in traditional fiat currencies.

CLIC Technology has its head office in Aventura, Florida. The Company lists on the OTC Markets. Market introduction of the new crypto-payment gateway system and related services is planned to take place in a phased rollout in the United States and other major markets in the coming months.

CLIC Technology is lending its services to the developing cannabis and CBD (cannabidiol) industries. The Company is joining forces with Chicago’s LeafyQuick CBD Delivery Service. LeafyQuick has opted to register for CLIC’s ClicPay online payment gateway pilot program, a cutting-edge cryptocurrency platform for merchants that will accept blockchain payments and convert them into local currency securely, all within 24 hours.

This program is a step towards the future for companies such as LeafyQuick. It permits them to sidestep burdensome regulations imposed by payment processors over an industry that experts predict will soon be worth upwards of $20 billion. The ClicPay Merchant Gateway will offer LeafyQuick and others like them a fast setup with simple integration. This is an option that gives the whole CBD industry the capability to start accepting cryptocurrency payments instantly.

CLIC Technology Chief Executive Officer, Roman Bond, said, “We are extremely excited to be working with LeafyQuick, and to be able to help move the CBD industry forward. Turning cryptocurrency into everyday fiat is going to be a game-changer for many in the industry.”

CLIC Technology, in collaboration with blockchain infrastructure provider and B2B platform Opporty, is ready to launch a progressive browser extension that will revolutionize the e-commerce industry. It will allow consumers to make everyday purchases on Amazon using the open source, public, blockchain-based distributed computing platform Ethereum.

Powered by Plasma Cash design pattern for off-chain processing of an on-chain assets provided by Opporty, the new extension will bring a modern day cryptocurrency economy one step closer to becoming a reality. The two companies plan to create payment platforms processing Ethereum, as well as any tokens based on ERC-20, ERC-721, and other Ethereum compatible standards. This will open up a host of possibilities for consumers to use digital currency in the e-commerce marketplace.

CLIC Technology, Inc. (CLCI), closed Monday's trading session at $0.08, up 41.5929%, on 4,200 volume with 5 trades. The average volume for the last 3 months is 11,921 and the stock's 52-week low/high is $0.009999999/$0.119999997.

Pacific Green Technologies, Inc. (PGTK)

Micro Cap Spot, The Headhunters, Last10k, Trading View, Marketbeat, InvestorsHub, Wallet Investor, Stockhouse, Simply Wall St, 4-Traders, Stockwatch, Market Exclusive, GlobeNewswire, Investors Hangout, MarketWatch, Dividend Investor, Stockopedia, and Market Screener reported earlier on Pacific Green Technologies, Inc. (PGTK), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Pacific Green Technologies, Inc. is the owner of the ENVI-Marine™ and ENVI-Clean (TME) Exhaust Gas Scrubbing Systems. The Company has developed a portfolio of patented, emission control technologies. These remove pollutants from marine engine, power plant and waste incinerator exhaust streams to meet increasingly stringent environmental standards. Its solutions utilize its patented “Turbo Head Technology™”. Established in 2011, Pacific Green Technologies is headquartered in San Jose, California.

The “Turbo Head Technology™” enables a more thorough mixing of exhaust gases and a chosen reagent solution, which delivers more effective contaminant removal in a system that is smaller and more efficient to build and operate. Pacific Green Technologies uses a global network of experts in the field of emissions control, with the technology proving to be very effective and cost efficient.

Moreover, the Company created a strategic joint venture (JV) with PowerChina SPEM, a unit of China's largest engineering, procurement, and construction firm. This JV is to support the manufacture, design, and installation of its solutions on a worldwide scale, while also serving as an in-country sales agent for commercial opportunities in mainland China. In August 2017, Pacific Green Technologies announced the signing of a Memorandum of Understanding (MOU) with PowerChina SPEM Co. Limited to incorporate a new company whereby Pacific Green Technologies own 50.1 percent and PowerChina SPEM 49.9 percent.

ENVI-Marine™ is a new generation of scrubbing technology. It has a simple patented design, no moving parts or media, and industry leading efficiency. In addition, the Company’s ENVI-Clean (TME) captures sulphur at the source before it pollutes the atmosphere.

In December 2018, Pacific Green Technologies announced that its wholly-owned subsidiary, Pacific Green Marine Technologies, Inc. (PGMT), executed an agreement to manufacture its System for 52 vessels owned or managed by Scorpio Tankers, Inc. (STNG). The Agreements provide for 42 vessels in 2019 and 10 vessels in 2020.

This past February, Pacific Green Technologies announced the appointment of Mr. Richard Oliver as Chief Financial Officer, a new position at Pacific Green, effective May 24, 2019. Before the start of Mr. Oliver’s employment, the Company’s Chief Executive Officer, Mr. Neil Carmichael, has served as Principal Financial Officer and Principal Accounting Officer, which roles will be assumed by Mr. Oliver. He is a finance professional with 33 years’ of financial accounting, auditing and management experience in manufacturing, fabrication and inventory management.

Pacific Green Technologies, Inc. (PGTK), closed Monday's trading session at $1.11, up 38.75%, on 25,576 volume with 37 trades. The average volume for the last 3 months is 5,274 and the stock's 52-week low/high is $0.620500028/$3.3499999.

MobileSmith, Inc. (MOST)

Market Exclusive, Zacks, YCharts, MarketWatch, Simply Wall St, Market Screener, Marketbeat, Wallet Investor, Last10k, InvestorsHub, Wallmine, GuruFocus, Business Insider, Capital Cube, Corporate Information, Stockopedia, Stockwatch, Proactive Investors, Trading View, 4-Traders, Dividend Investor, and Stockhouse reported earlier on MobileSmith, Inc. (MOST), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MobileSmith, Inc. is a leader in the digital health and mobile development sector. It provides operational improvement member-facing mobile application (app) services to the healthcare industry in the U.S. The Company helps its clients improve health outcomes, patient satisfaction and grow profit margins using its toolbox of proven mobile app technologies. OTCQB-listed, MobileSmith has its corporate office in Raleigh, North Carolina.

The Company is changing healthcare one app at a time through targeting the evident inefficiencies in the U.S. healthcare delivery model. Greater than 60 healthcare systems and organizations are partnering with MobileSmith Health to deliver a new healthcare experience and embrace the impact of technology as an agent of change. Fundamentally, MobileSmith is helping its clients meet their healthcare consumers where they are, on their mobile devices, to expand the reach of providers to modify behavior with apps that remind, educate, track, and also engage the patients that use them.

MobileSmith is focusing on select patient segments that struggle with areas such as medication adherence, discharge instruction compliance, and health literacy, and provide new unique digital patient experiences including indoor navigation and clinic “check-ins”, which directly improve critical patient satisfaction.

Via the use of MobileSmith Health Blueprints, hospitals and other healthcare organizations can customize their apps based on specific feature sets, workflow, branding, protocol, procedure and service line. This is while launching in as little as 90 days. MobileSmith’s latest Blueprints 3.0 offerings provide expanded mobile capabilities across the Company’s main applications: In-Network Apps, Perioperative Apps, and Patient Acquisition apps. Additional Blueprint 3.0 features include key mobile-specific functionality such as self-triage, remote check-in, wayfinding and EMR interoperability.

Recently, MobileSmith Health announced a collaboration with Kaweah Delta Medical Center on the release of a surgery app. This app provides patients and caregivers with timed notifications, digital trackers and interactive resources about what to expect before, during and after surgery. The Kaweah Delta Surgery App was developed using MobileSmith Health’s signature Blueprints.

MobileSmith Health also recently announced the launch of Perioperative Blueprints 4.0. The expanded app Blueprints include new functionality, which tailors the patient experience pre- and post-op with the introduction of “Peri,” which offers AI-based (Artificial Intelligence) interactions that elevates patient literacy with conversational interfaces, video, as well as images. EMR integration and new adherence tracking dashboards permit providers to readily assess risk factors for complications, cancellations or readmissions.

MobileSmith, Inc. (MOST), closed Monday's trading session at $2.80, up 59.0909%, on 11,550 volume with 11 trades. The average volume for the last 3 months is 2,528 and the stock's 52-week low/high is $1.00/$5.50.

Bespoke Extracts, Inc. (BSPK)

Simply Wall St, Stockopedia, InvestorsHub, Wallmine, Stockhouse, Ventureline, GuruFocus, Investors Hangout, Barchart, Wallet Investor, Infront Analytics, YCharts, Market Screener, Morningstar, Market Exclusive, Marketwired, Insider Financial, and MarketWatch reported earlier on Bespoke Extracts, Inc. (BSPK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bespoke Extracts, Inc. is a producer of high quality, flavorful, hemp-derived cannabidiol (CBD) extract products. The Company established in early 2017 to introduce a proprietary line of premium quality, all-natural CBD products in the form of tinctures and capsules for the nutraceutical and veterinary markets. Bespoke Extracts is headquartered in Sunny Isles Beach, Florida. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s products are marketed as dietary supplements and distributed through the Company’s direct-to-consumers e-commerce store. Bespoke’s products are produced using pure, all natural, zero-THC phytocannabinoid-rich (PCR) hemp-derived CBD. CBD is non-psychoactive. CBD (cannabidiol) is one of over 85 cannabinoids found in cannabis. CBD is present in more significant quantities in hemp than it is marijuana.

Bespoke Extracts’ mission is to become one of the world’s most trusted sources for premium quality, all-natural, USA-grown, hemp-derived cannabidiol (CBD) products for the nutraceutical and veterinary markets. The Company strives to use only vegan, Fair Trade Certified, and organic ingredients with fast acting benefits for anyone looking for an alternative remedy. Bespoke’s farmers have been innovators in hemp agriculture, farming practices, agrotech, as well as production for generations. Bespoke’s hemp is stable, high in CBD, low in THC, and resistant to pathogens and pests.

The Company’s products include Sport Lemon Lime Tincture – THC Free 1500MG; CBD Manuka Honey Tincture; and CBD Bacon Flavored Pet Tincture. Moreover, products include CBD Softgel Capsules; CBD Pain Relief Cream; and CBD Isolate Powder.

Bespoke Extracts announced this past November that its Board of Directors appointed Niquana (Nikki) Noel as President and Chief Executive Officer (CEO), effective immediately. Serving Bespoke as its Operations Manager, Noel assumed day-to-day leadership of the Company and joined its Board of Directors. Noel has spent close to two decades working with privately-held and publicly-traded micro and small cap companies.

Bespoke Extracts, Inc. (BSPK), closed Monday's trading session at $0.03, up 77.5148%, on 2,530,418 volume with 185 trades. The average volume for the last 3 months is 57,965 and the stock's 52-week low/high is $0.006/$0.041000001.

The QualityStocks Company Corner

180 Life Sciences Corp.

The QualityStocks Daily Newsletter would like to spotlight 180 Life Sciences Corp..

Special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) completed its IPO in June 2017. The corporation raised $115 million intending to find and acquire a company with a strong value proposition primarily in the United States healthcare or healthcare-related industry. In July 2019, KBL Merger Corp. IV signed a definitive business combination agreement for a merger with 180 Life Sciences Corp. (formerly known as CannBioRx Life Sciences Corp.), contingent on approval from KBL Merger Corp. IV. In June 2020, KBL Merger Corp. IV had completed bridge financing for the acquisition of 180 Life Sciences, which was valued by KBL at $175 million. KBL utilized share swapping to carry out the purchase.

KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (SPAC), announced that, in connection with its previously detailed merger agreement with 180 Life Sciences, it consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on August 28, 2020. It expects to close the business combination in Q4 2020. Following the merger, the company will be listed on the Nasdaq Capital Market under ticker symbol ‘ATNF’.

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University.

KBLM has valued 180 Life Sciences at $175 million, with the acquisition being carried out via a share swap through which each share of 180 Life Sciences will be exchanged for one share of KBLM.

Drug Development Programs

180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies.

The company’s primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trials with first results expected in 2021. Further clinical trials are scheduled to begin by the end of 2020. The company has two additional programs that are in the preclinical stage and are showing promising results.

  • Fibrosis & Anti-TNF (Phase 2b/3 Trials): Based at the Kennedy Institute within Oxford University, the fibrosis and anti-TNF program is being led by Professor Jagdeep Nanchahal, a surgeon-scientist who has been running the phase 2 trials, and Professor Sir Marc Feldmann, a renowned immunologist and one of the pioneers of anti-TNF therapy. The program is designed to address four critical areas of inflammation:
    1. The phase 2b/3 trial evaluating the treatment of early stage Dupuytren’s disease (DD) is a fully grant-funded and enrolled study, with top line data expected to be available by Q4 2021.
    2. The phase 2b trial studying the treatment of frozen shoulder is likewise grant-funded and is scheduled to be initiated by Q3 2021.
    3. The phase 2 trial in post-operative cognitive deficit (POCD) is anticipated to commence in Q4 2021.
    4. Preclinical studies in liver fibrosis and nonalcoholic steatohepatitis (NASH) are set to begin in late 2020.
  • Inflammatory Pain (Preclinical): Directed by Professor Raphael Mechoulam at the Hebrew University in Israel, this program is focused on discovering novel compounds to treat chronic inflammatory pain.
  • A7nAChR (Preclinical): Led by Professor Lawrence Steinman and Dr. Jonathan Rothbard, 180 Life Sciences is seeking to develop a treatment for ulcerative colitis in ex-smokers by targeting the a7nAChR, a nicotine receptor in the body and a central factor in the body’s method of controlling inflammation.

Market Size for Anti-Inflammatory Medication

According to a study carried out by Allied Market Research, the anti-inflammatory therapeutics market is expected to grow to an approximate $106.1 billion annual market size in 2020, registering a CAGR of 5.9% during the period from 2015 to 2020.

Ranging from asthma treatments to targeting the causes of diseases such as arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease, anti-inflammatory therapeutics have seen a sharp increase in usage, particularly given that they allow for medical responses that are more targeted and effective while possessing lesser side effects relative to conventional drugs.

Management Team

Professor Sir Marc Feldmann, Co-Chairman, is known to be a pioneer of anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. As of today, anti-TNF therapy drugs have become the world’s largest drug class, with sales estimated at over $40 billion per annum. Feldmann has received seven international awards for biomedical innovation over the years, including the Crawford and Lasker awards, and he is a member of the Royal Society.

Professor Lawrence Steinman, Co-Chairman, is a scientific luminary, having discovered the role of integrins, which led to the creation of Natalizumab, a highlight effective treatment for multiple sclerosis and inflammatory bowel disease. Steinman is a member of the National Academy of Sciences and has received four international awards for biomedical innovation, including the Charcot Prize. Prior to joining 180 Life Sciences, Steinman founded Centocor, a pharmaceutical company that was sold to Johnson & Johnson for $4.9 billion.

Dr. James N. Woody, CEO, was instrumental in the discovery of Remicade as Chief Scientific Officer at Centocor. Previously, Woody founded Avidia and Proteolix, both of which were subsequently sold to Amgen, and he was a General Partner at Latterell Venture Partners. Boasting over 25 years of pharmaceutical research and management experience, Woody was also previously the general manager of Roche Biosciences, the former Syntex Pharmaceutical Company.

Investment Considerations

  • 180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value.
  • The company has a large and expanding patent portfolio.
  • The risks associated with the company’s drug development efforts are mitigated through the concurrent advancement of multiple programs in different stages of development.
  • 180 Life Sciences decreases costs and expedites time to market through the use of grant funding, cost-effective international trials and recruitment of hospital-based luminaries who attract teams of excellence.

Recent News

chart

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF)

The QualityStocks Daily Newsletter would like to spotlight LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF).

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, on Friday announced its engagement of Tailwinds Research Group to provide digital content distribution for the company. According to the update, the engagement will cover a 1-year term, at US$2,500/month with 100,000 stock options provided at C$0.88/option. In addition, LexaGene today released a video message from its founder and CEO, Dr. Jack Regan, that highlighted the company’s progress toward commercial sales and announced the appointment of Dr. Shelley Rankin to LexaGene’s Scientific Advisory Board. To view the full press release, visit http://ibn.fm/xZQYx and http://ibn.fm/itMfkXXXX.

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) is a molecular diagnostics company that develops genetic analyzers for rapid detection of pathogens at the point-of-need.

Based in the greater-Boston, Massachusetts area, the company’s fully automated genetic analyzer for pathogen detection, the MiQLab™, is designed to deliver reference-quality data with ease of use. MiQLab’s technology screens samples for up to 27 different targets at once—looking for pathogens and antimicrobial resistance factors—and returns results in approximately one hour. It is designed to be operated at the site of sample collection to avoid the delay associated with shipping and manually processing samples. This technology is designed for use in multiple markets, including human and veterinary diagnostics, as well as food safety testing ($12.9B, $2.2B, and $23.4B markets, respectively).

Portfolio Benefits

Rapid, automated pathogen detection

LexaGene’s MiQLab pathogen detection system offers rapid and sensitive testing to markets in need of better vigilance against pathogens that could endanger health and harm public safety and the bottom line. The company’s disruptive technology is on-demand and offers results in approximately an hour.

End users collect a sample, load it onto the MiQLab genetic analyzer with a sample preparation cartridge, enter a sample ID and press ‘go’.

MiQLab is open-access, which allows users to easily customize their own tests, in addition to running the company’s own validated tests. No comparable technology exists on the market today for automating customized testing. The open-access market is over $20 billion in value and includes industries like pharma and biotech that currently need an automated method of performing PCR testing in a cost-efficient way.

Improved COVID-19 Testing

As the COVID-19 pandemic continues to pose a threat to global safety, the need for improved testing procedures has been well established. LexaGene’s technology is automated and designed to be used at the point-of-need, thereby avoiding the 12- to 24-hour shipping time. Plus, it performs sample preparation and the gold standard RT-PCR chemistry for exceptional data quality in about one hour.

Because LexaGene’s open-access instrument can be rapidly configured to detect novel pathogens, it is ideally suited to prevent pandemic spread with its easily deployed testing that facilitates rapid quarantine-related decision making.

This speed is in stark contrast to competitor point-of-care technologies that have reagents pre-embedded into complex and expensive cartridges that are only manufactured at specialized production sites – making it impossible to rapidly meet a swift increase in demand.

According to Dr. Jack Regan, LexaGene’s CEO and founder, the world needs easy-to-use, fully automated pathogen detection instruments operating at points-of-need that can be equipped with tests to detect a novel pathogen within a week of knowing its genetic sequence. For this pandemic, the lack of such technology forced the majority of testing to occur in distant reference laboratories, making rapid decisions on quarantine impossible and making the likelihood of successful containment remote.

Regan explained in a press release (http://nnw.fm/Vz5Ju), “LexaGene expects to be the first company to commercialize an automated open-access microfluidic technology designed for use at the point-of-need that can be configured to detect a novel pathogen in just a week’s time of its emergence – for use on-site to return results in one hour – and improve our chances of successful containment.”

Market Potential

LexaGene’s technology has a wide range of applications across many other markets, including biotech and pharma testing, water quality monitoring, agricultural testing, biodefense, and use at point-of-need at border crossings, military bases, aircraft carriers and cruise ships.

Markets for customized testing solutions are poised for significant growth. Industry analysts forecast considerable expansion of many of LexaGene’s potential target markets in the coming years, including:

  • The genotyping sector, forecast to reach a valuation of $31.9 billion by 2023;
  • PCR assays, expected to make up a $7 billion market opportunity by 2026;
  • The sample prep market, forecast to eclipse $9.3 billion by 2025;
  • Water quality monitoring, set to grow to $1.59 billion by 2022; and
  • Agricultural testing, anticipated to reach $6.29 billion by 2022.

LexaGene’s patented microfluidic system was invented by company CEO Regan, a leading scientist who developed a bio-warfare surveillance instrument that has been adopted by the Department of Homeland Security. Regan is also known for developing an instrument that detects respiratory pathogens from nasal swab samples. The development of these instruments was supported by $20 million in government funding.

Management Team

LexaGene’s experienced leadership team drives company growth with a focus on innovation, pursuing unique market opportunities and providing shareholder value.

Dr. Jack Regan, Chief Executive Officer & Director, is the inventor of the company’s flagship automated pathogen detection technology, the MiQLab. Before founding LexaGene, he led a team of scientists at Bio-Rad Laboratories (NYSE: BIO) in developing tests for detecting pathogens, cancer and neurological disorders using droplet digital PCR. Prior to Bio-Rad, Regan helped QuantaLife, a startup company, bring its product from concept to commercialization, where it was subsequently acquired by Bio-Rad. He has also worked at Applied Biosystems/Life Technologies on automated sample preparation and did his post-doctoral training at Lawrence Livermore National Laboratory. His doctoral training at the University of California San Francisco focused on influenza viral replication.

Daryl Rebeck, President, has over 20 years of capital market experience with an established international financial network. Rebeck was a vice president and senior investment advisor with Canada’s largest independent investment bank, Canaccord Genuity, where he was responsible for raising significant risk capital for growth companies, with a particular focus on natural resources and medical technology. He has since worked to provide management expertise and grow shareholder value. He served as senior VP of corporate finance of Auryn Resources (NYSE: AUG), a $250 million market cap mining exploration company.

Jeffrey Mitchell, CFO, boasts over two decades of financial and SEC experience. Before joining LexaGene, he served as controller and director of finance, overseeing areas such as public company financial reporting, audits, and financial planning and analysis for Palomar Medical Technologies Inc. In addition to his many years at Palomar, Mitchell has served in numerous financial and strategic advisory roles for medical device, imaging and diagnostic companies.

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF), closed Monday's trading session at $0.65, up 3.0496%, on 262,260 volume with 170 trades. The average volume for the last 3 months is 389,428 and the stock's 52-week low/high is $0.303799986/$0.928245007.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF).

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) was featured today in a publication from MiningNewsWire, examining how, according to a report, Tesla Inc. (NASDAQ: TSLA) is working on a collaboration with a Canadian mining company to help develop a mine that would provide Tesla a source for low carbon nickel that is used in its lithium-ion batteries. In the company’s mission statement presented by Elon Musk, it is stated that the company’s aim, apart from manufacturing eco-friendly cars, was to achieve environmentally friendly means of production.

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: ATUMF), closed Monday's trading session at $0.32, up 8.6809%, on 126,622 volume with 36 trades. The stock's 52-week low/high is $0.109999999/$0.446000009.

Recent News

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, this morning announced that its wholly owned subsidiary, Central Florida Arborcare, has been awarded a one year contract with Lake County Florida, beginning October first 2020. The contract, which is intended to supply right of way tree trimming and related services to the county, includes four one year renewals. To view the full press release, visit https://nnw.fm/yOheJ.

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.

Leadership

SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

  • Tony Raynor, Chief Executive Officer
  • Edward Lee, Chief Operating Officer
  • Ralph Spencer, Director of Business Development, Strategic Acquisitions
  • Steve Ogden, ISA-Certified Arborist
  • Rick Starcher, Master Chemist
  • Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Monday's trading session at $1.50, even for the day, on 202 volume with 3 trades. The stock's 52-week low/high is $0.05/$2.4999001.

Recent News

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

Pac Roots (CSE: PACR), a Canadian cannabis company dedicated to producing premium-quality strains and products, focuses on its first-mover approach to produce premium-quality, industry-leading cannabis strains unavailable in the regulated market. The company’s premium-grade cannabis strains are used in a wide variety of products. To view the full article, visit: https://cnw.fm/ELaBz.

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

  • Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
  • Continued stress testing for indoor, high yield, THC and medicinal genetics
  • Continued stress testing for outdoor, high yield, THC and medicinal genetics
  • Exotic, genetic cloning for the luxury, high margin, cannabis flower market
  • Psychoactive/medicinal ratio testing for effect and
  • Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

  • Global testing in different microclimates to assess genetic and complete systems for optimal yields
  • Data collection, testing and optimization to prove process for commercial implementation and
  • High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Monday's trading session at $0.26, even for the day. The average volume for the last 3 months is 21,821 and the stock's 52-week low/high is $0.11/$0.73.

Recent News

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, together with HMC HealthWorks, a 40-year veteran in health-care management with clinically-integrated models of care that reduce health-care costs and improve population health, today announced entry into a sales and distribution agreement. Under the partnership, HMC will incorporate DarioHealth's digital therapeutics solution into its care management programs on a stand-alone basis as well as for incorporation within HMC’s comprehensive solutions. To view the full press release, visit http://ibn.fm/f9gRq.

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Monday's trading session at $18.55, off by 2.1108%, on 53,809 volume with 543 trades. The average volume for the last 3 months is 257,933 and the stock's 52-week low/high is $3.01999998/$22.4899005.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element Inc. (NASDAQ: NETE) was featured today in a publication from Green Car Stocks, examining how, up until the mid-90s to the mid-2000s, anyone looking to purchase a vehicle either for personal or commercial use had to choose between gasoline and diesel-powered vehicles. Over the years, however, technological advancements made battery-powered electric vehicles (“EVs”) a viable option. Additionally, as the long term effects of climate change became clearer, plenty of state governments have started incentive programs to promote or encourage customers to switch to electric vehicles. Such programs have made EVs much more affordable, thus granting a larger customer base access to the EV market.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Monday's trading session at $6.13, off by 1.4469%, on 132,267 volume with 825 trades. The average volume for the last 3 months is 842,566 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group (NASDAQ: MEDS) was featured today in a publication from NetworkNewsWire, examining how, a Kaiser Family Foundation (“KFF”) poll conducted last year found that 24 percent of its respondents had difficulty affording prescription drugs and 29 percent of all adults reported not taking their medicines as prescribed during the previous year because of the cost, relying instead on strategies such as not filling a prescription, taking an over-the-counter drug instead, or cutting pills in half or skipping a dose (http://nnw.fm/AHsjL). As the COVID-19 pandemic was just beginning to explode on American soil this spring, The Hill reported 34 million people knew at least one friend or family member who died in the last five years because they could not afford the medication to treat their condition (http://nnw.fm/MZvj9). The pandemic has made access to reasonably priced medicine and medical supplies more critical than ever as people seek ways to maintain their care while limiting their exposure to infection from a potentially deadly new virus. Before the virus even appeared on the international scene, pharmaceutical supplies and services provider Trxade Group (NASDAQ: MEDS) was busy building a supply chain trading platform that supports small, community-based pharmacies trying to compete with national chains, and services that help consumers use available smart technology to consult with physicians and obtain their medications without having to leave home.

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Monday's trading session at $4.80, off by 4.9505%, on 45,376 volume with 203 trades. The average volume for the last 3 months is 51,430 and the stock's 52-week low/high is $4.01000022/$11.6000003.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company") is pleased to announce that it has been advised by the U.S. Department of Energy ("DOE") Office of Fossil Energy ("FE") and the National Energy Technology Laboratory ("NETL") of their intent to award a contract to Energy Fuels, working with a team from Penn State , to evaluate and develop a conceptual design to allow for the commercial production of mixed rare earth oxides ("REO") from coal-based resources in an environmentally benign fashion. Furthermore, the DOE has the option to award Energy Fuels a contract for the completion of a feasibility study on this initiative.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon-free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Monday's trading session at $1.66, off by 7.2626%, on 1,437,779 volume with 3,818 trades. The average volume for the last 3 months is 1,577,484 and the stock's 52-week low/high is $0.779999971/$2.3499999.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) was featured today in a publication from BioMedWire, examining how, as we all know by now, the best way to help stop the spread of coronavirus is getting a coronavirus test done and wearing a mask, of course. A test reveals whether a person is negative or positive. A negative test result means an individual does not have the virus while a positive result means that one does have the virus. Also today, BioMedWire covered how POAI announced that one of its executives, Helomics CIO Mark Collins, PhD, recently appeared on DojoLIVE! (https://ibn.fm/hSAn4). Helomics, a POAI subsidiary, applies artificial intelligence to its rich data gathered from more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Monday's trading session at $0.855, off by 0.581395%, on 358,240 volume with 635 trades. The average volume for the last 3 months is 843,619 and the stock's 52-week low/high is $0.810000002/$6.25.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the direct-selling industry and network marketing is well positioned within the industry, which continues to record healthy growth, as reported by the World Federation of Direct Selling Associations (“WFDSA”) (http://nnw.fm/dH5W7). In its latest report, “2019 Direct Selling Business Results,” the WFDSA announced that worldwide retail sales showed a year-over-year sales increase of 1.4% compared to 2018 while growing at a healthy pace in the long term with five-year CAGR of 2.3% (excluding China).

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Monday's trading session at $0.27, off by 12.9032%, on 182,072 volume with 54 trades. The average volume for the last 3 months is 364,616 and the stock's 52-week low/high is $0.0215/$0.730000019.

Recent News

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (OTCQB: SGMD) was featured today in the 420 with CNW by CannabisNewsWire. Despite being insanely profitable, the nascent cannabis industry still has plenty of kinks to work out. At the moment, the industry lacks a cohesive, nationwide regulatory structure and this has allowed plenty of lower quality products to slip through. Studies have found that a statistically significant portion of cannabis products on the market are either contaminated with heavy metals or do not contain what is stated on their labels. That’s what makes third party testing coupled with barcode labeling so crucial to the industry’s long term survival.

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

  • Geographic expansion of Budcars delivery scope
  • New delivery geographies
  • Cannabis cultivation as a key component of a hybrid vertical integration strategy
  • Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Monday's trading session at $0.0015, off by 14.2857%, on 114,044,161 volume with 298 trades. The average volume for the last 3 months is 64,126,687 and the stock's 52-week low/high is $0.001399999/$0.021999999.

Recent News

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF)

The QualityStocks Daily Newsletter would like to spotlight Exro Technologies Inc. (OTCQB: EXROF).

Exro Technologies (CSE: XRO) (OTCQB: EXROF), a leading technology company that has developed a new class of power electronics for powertrains, today announced that it has been accepted for listing on the TSX Venture Exchange (the "TSXV"). Per the update, Exro Technologies’ common shares will commence trading on the TSXV under the symbol "EXRO" on Tuesday September 22, 2020. "The listing of our common stock on the TSX Venture Exchange is an important milestone for Exro," said Exro CEO Sue Ozdemir in the press release. To view the full press release, visit http://nnw.fm/MFE9Y

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), a Canadian technology company, is an innovative pioneer in the energy sector. Exro has developed and commercialized an electric power module (EPM) that integrates into existing motor systems to make them smarter. Exro’s patented technology optimizes existing motor performance by automatically sensing and adapting operating parameters to an optimized state, creating measurable efficiency gains, reduced mechanical components and increased system availability.

Applications

Exro’s technology and efficiency optimization algorithms improve the performance and efficiency of electric motors by manipulating power delivery to individual coils, thereby enabling the ability to expand operating parameters. This novel approach is scalable and can be utilized in most variable torque applications.

The widespread applications of Exro’s technology apply to optimizing the performance of electric vehicles, locomotive traction applications, industrial motors, and other variable torque applications that benefit from smart energy conversion.

Intellectual Property

Exro’s proprietary, patented software controls electric motor coils through individual coil switching. This introduction of intelligence into energy conversion at the level of individual coils results in expanded speed/torque capability, improved machine efficiency, reliability, safety and maintenance across a wider operating range. Exro’s advanced control algorithms create smart, real-time optimized power management.

Exro currently holds 15 patents, with 8 patents pending and additional patents under development. The company continues to expand its IP portfolio to support its goal of becoming a globally recognized leader in leveraging advanced control algorithms to improve the performance, efficiency and longevity of electric motors and generators.

Market Opportunity

Electric motors are the single biggest consumer of electricity. They account for about two-thirds of industrial power consumption and about 45% of global power consumption, according to an analysis by the International Energy Agency. Exro’s technology seeks to give industries a new way to look at energy—from electric vehicles, to industrial equipment, to renewable applications like wind farms; we are improving the way energy is consumed.

Laboratory Expansion

The 6,500-square-foot Exro Innovation Center (EIC), scheduled to open spring of 2020 in Calgary, will transition the current Victoria lab into one Calgary based center. The company’s new laboratory space will expand its service capabilities to customers, provide larger test capabilities, and showcase how Exro’s technology can be applied to dramatically improve the performance of electrical motors.

The EIC will also host collaborative events to explore advances in energy consumption and electric motor innovations, with participants from across Canada and around the world.

Strategic Partnerships

  • A strategic agreement with Finland’s Aurora Powertrains Oy, which in 2019 released an all-electric production snowmobile called the “eSled,” will see Exro’s technology added to the Aurora electric powertrain. The snowmobile sector’s economic footprint is estimated at $26 billion in the U.S., $8 billion in Canada, and $5 billion in Europe and Asia.
  • An agreement with Potencia in Mexico serving the last mile vehicle segment will integrate Exro’s custom drive and EPM module into small passenger commercial vehicles (taxis) and fleet delivery trucks
  • A licensing agreement with Motorino Electric, a leader in the Canadian electric transportation industry, will integrate Exro’s Electric Power Module technology into Motorino’s CTi electric bicycle.

Management

Chief Executive Officer Sue Ozdemir is a proven leader in the innovation and manufacturing of electric motors. She has nine years of accomplishments at General Electric, acting as CCO and the CEO of GE’s Small Industrial Motors Division, overseeing the division’s North American and international markets – ultimately building the division into a $160 million enterprise.

Chief Commercial Officer Josh Sobil is leading the seamless adoption of Exro’s growing product portfolio focused on the mobility segment and opening doors in all segments including agriculture, heavy industry, energy, construction, among others.

Executive Chairman Mark Godsy is a serial technology entrepreneur who has been involved in many top tier ventures, including two of Canada’s most successful biotech companies.

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), closed Monday's trading session at $0.9394, up 4.8438%, on 548,300 volume with 403 trades. The average volume for the last 3 months is 344,622 and the stock's 52-week low/high is $0.150000005/$1.14999997.

Recent News

Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF).

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced that it has successfully developed a scalable process, with demonstrated production at 500 litre scale, for producing cannabigerol ("CBG") with greater than 99% purity and no detectable tetrahydrocannabinol (“THC”). To view the full press release, visit https://cnw.fm/Q9YN3

Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (OTCQX: CANSF), closed Monday's trading session at $0.5836, up 7.3781%, on 16,421 volume with 11 trades. The average volume for the last 3 months is 41,029 and the stock's 52-week low/high is $0.218999996/$0.738600015.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.